ZBIO

ProShares UltraPro Short NASDAQ Biotechnology

Delisted

ZBIO was delisted on the 27th of March, 2020.

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 70%
Negative

Positive
MarketBeat
4 days ago
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
A pivotal clinical development has sent Zenas BioPharma NASDAQ: ZBIO shares climbing higher, reshaping the company's investment profile overnight. On Oct. 27, 2025, Zenas BioPharma's stock price climbed by over 30% on exceptionally high trading volume, pushing its market capitalization to approximately $1.35 billion and hitting a new 52-week high of over $34.
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
Neutral
GlobeNewsWire
5 days ago
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 -
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Neutral
24/7 Wall Street
15 days ago
Insiders Bet Big on These 3 Fintech and Biotech Stocks
The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.
Insiders Bet Big on These 3 Fintech and Biotech Stocks
Neutral
The Motley Fool
16 days ago
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
Leon O. Moulder, the founder, Chief Executive Officer, and Chairman of the Board of Directors, acquired 36,928 shares of Zenas BioPharma (ZBIO -7.97%) on October 7, 2025, through an open-market purchase, as disclosed in the SEC Form 4 filing.
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
Positive
Seeking Alpha
23 days ago
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal
Zenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and orelabrutinib, drive optimism, with topline Phase 3 INDIGO trial data for obexelimab expected in late 2025. Strong cash position and recent private placement provide operational runway through 4Q26, supporting ongoing clinical development and mitigating dilution risks.
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal
Positive
Reuters
24 days ago
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from China-based InnoCare Pharma for multiple sclerosis and other autoimmune conditions under a licensing deal potentially worth more than $2 billion.
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
Neutral
GlobeNewsWire
24 days ago
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) -
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
Neutral
GlobeNewsWire
2 months ago
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept.
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
Neutral
GlobeNewsWire
2 months ago
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September:
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates